# Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

> **NCT00379080** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Adult Brain Tumor
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **PROCEDURE:** conventional surgery
- **DRUG:** tandutinib
- **OTHER:** pharmacological study
- **OTHER:** Tissue samples

## Key facts

- **NCT ID:** NCT00379080
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-09
- **Final completion:** 2013-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379080, "Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00379080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*